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Abstract
Background: The etiology and immunopathology of multiple sclerosis (MS) is not well understood. It is recognized
that although autoreactive T cells are the main early mediators of disease, other cell types, including cells of the
innate immune system contribute to MS pathogenesis. The objective of this study was to determine if Toll-like
receptor (TLR) signaling is functionally altered in patients with MS.
Findings: Peripheral blood mononuclear cells from healthy donors and patients with relapsing remitting MS were
stimulated with specific agonists of TLRs 3, 7, 8 and 9. Using quantitative polymerase chain reaction transcript levels
of tumor necrosis factor-α, interferon-α and interleukin (IL)-12β were quantified from patients with MS and healthy
donors. TLR8-induced production of IL12B transcripts and protein was functionally impaired in patients with MS as
compared to healthy controls (P <0.05 and P <0.005, respectively). Patients with MS also expressed lower baseline
levels of TLR8 as compared to healthy controls (P <0.05).
Conclusions: TLR8 expression and signaling is impaired in peripheral blood mononuclear cells from patients with
MS. This finding suggests that loss of TLR8 signaling may be contributing to autoimmune processes in MS.
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Findings
Multiple sclerosis (MS) is an autoimmune disorder charac-
terized by demyelination, chronic inflammation, and neur-
onal damage primarily caused by activated, auto-reactive
CD4+ and CD8+ T cells directed against myelin [1]. Com-
binations of genetic and environmental factors, including
pathogens, are believed to trigger the abnormal immune
activation in MS [2]. Pathogens which initiate innate im-
mune responses in the central nervous system (CNS) via
Toll-like receptor (TLR) signaling may lead to the develop-
ment of autoreactive T cells due to antigen spread in a
process known as bystander activation [2,3].
TLRs are pattern recognition receptors (PRRs) that
recognize conserved pathogen-associated molecular pat-
terns (PAMPs) [4]. TLRs responsible for detecting viral
PAMPs include TLR3, which detects viral double stranded
(ds)RNA, TLR7 and TLR8, which detect viral single
stranded (ss)RNA, and TLR9, which detects dsDNA and
are located in the endosome [5,6]. TLR signaling results
in the activation of T cells [7] and production of pro-
inflammatory cytokines, such as interleukin (IL)-12β,
interferon (IFN) and tumor necrosis factor (TNF)-α, which
are known to be increased in patients with MS [5,8,9].
Many studies have implicated TLRs in the pathophysiology
of MS and experimental autoimmune encephalomyelitis
(EAE) [4]. For instance, activation of TLRs reliant on the
downstream adaptor protein MyD88 (TLR7, 8 and 9) may
enhance MS progression, while the activation of TLR3,
which is not dependent on MyD88, may be protective in
neurons [4,10]. However, it remains unclear if TLR signal-
ing is functionally dysregulated in patients with MS prior
to treatment. To better understand the role of TLR signal-
ing in MS, we sought to determine the functional proper-
ties of TLRs 3, 7, 8 and 9 in these patients as compared to
healthy donors.
To determine if patients with MS had dysregulated
TLR signaling we analyzed the transcriptional response
of IL12β, IFN-α and TNF-α to TLR3, 7, 8 and 9 stimula-
tion. Briefly, peripheral blood mononuclear cells (PBMC)
were obtained from clinically stable untreated patients
with relapsing remitting MS (n = 10) and from healthy
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age- and gender-matched donors (n = 10). Patients with
MS were aged from 49 to 74 years (median 57 years;
seven females and three males). Healthy donors ranged
in age from 41 to 72 years (median 57.5; seven females
and three males). All patients and donors gave informed
consent and this study was approved by the Office of
Human Subjects Protection and Research at the Na-
tional Institutes of Health. PBMCs from healthy donors
and patients with MS were isolated by a standard oper-
ating procedure using Ficoll-Isopaque density gradient
centrifugation (Gibco, Life Technologies Ltd., Paisley,
UK) and were immediately stored in liquid nitrogen
until further use. Cells from controls and patients with
MS were processed under the same protocol. Cells
were maintained in Iscove’s Modified Dulbecco’s Media
(Invitrogen, Carlsbad, CA, USA) supplemented with
10% (v/v) human serum (Sigma, St. Louis, MO, USA)
and 1% (v/v) antibiotic-antimycotic mixture (Invitrogen)
at 37°C with 5% CO2. PBMCs were plated at 1.5 × 10
6
cells/well and treated with either media (unstimulated),
phytohaemagglutinin (PHA) (0.025 μg/mL), TLR3 ligand,
Poly(I:C) (10 μg/mL), TLR7 ligand, Imiquimod (25 μg/mL),
TLR8 ligand, ssPolyU/LyoVec (10 μg/mL) or TLR9 ligand,
ODN2216 (0.025 μg/mL) for six hours at 37°C. All ligands
were obtained from InvivoGen (San Diego, CA, USA).
After incubation, cells were collected and total RNA was
extracted using the QIAGEN RNeasy Plus kit (Qiagen,
Germantown, MD, USA). Up to 100 ng of RNA from each
sample was reverse transcribed into cDNA per the manu-
facturer’s instruction using the SuperScript III First-Strand
Synthesis SuperMix for quantitative-PCR (Invitrogen).
Gene expression levels for IFNA2, TNFA, IL12B and glyc-
eraldehyde 3-phosphotate dehydrogenase (GAPDH) were
determined by quantitative PCR performed on a ViiA™ 7
Real-Time PCR System (Applied Biosystem, Carlsbad,





































































































































































































































































































































































Figure 1 PBMC cytokine gene expression levels after TLR stimulation. (A) IL-12B transcripts were decreased in patients with MS as
compared to healthy donors after Toll-like receptor (TLR) 8 stimulation (Student’s unpaired two-tailed t-test, * = P <0.05, n = 10 per group) but
not after TLR 3, TLR 7 or TLR 9 stimulation. (B) There was no difference between patients with MS and healthy donors in IFN-alpha transcript
production after TLR stimulation. (C) TNF-alpha transcripts were decreased in patients with MS as compared to healthy donors after TLR 3
stimulation (Student’s unpaired two-tailed t-test, * = P <0.05, n = 10 per group) but not after TLR 7, TLR 8 or TLR 9 stimulation. Data shown are
median ± 25% to 75% interquartile range relative gene expression of each cytokine normalized to GAPDH and a reference sample. PBMC,
peripheral blood mononuclear cells.
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from Origene (Origene, Rockville, MD, USA). Cytokine
transcript expression levels were determined by relative
quantification (ΔΔ Ct method [11]) for each individual
using GAPDH for normalization. Cells from patients
with MS showed a 58-fold decrease in transcript levels
of IL12B in response to TLR8 stimulation (median ±
25% to 75% interquartile range = 179.3 ±± 56.0 to 896.0
versus 10,518 ± 1,607 to 48,932 relative expression;
P <0.05) (Figure 1A), but no difference was detected after
TLR3, TLR7 or TLR9 stimulation. No significant differ-
ence was found between patients with MS and healthy
donors in production of IFNA with any TLR stimulation
(Figure 1B). Patients with MS showed a two-fold decrease
in transcript levels of TNFA in response to TLR3 stimula-
tion (median ± 25% to 75% interquartile range = 0.9 ± 0.4
to 1.0 versus 1.8 ± 1.1 to 1.9 relative expression; P <0.05)
as compared to healthy donors (Figure 1C), but not after
TLR7, 8 or 9 stimulation.
As MS is a hyper-inflammatory disorder and as IL-
12 is known to be elevated in patients with MS [12],
we were surprised to see a decrease in IL12B produc-
tion from patients with MS. We, therefore, confirmed
these results by determining the concentration of IL-
12p40 produced after TLR8 stimulation. Briefly, 1.5 ×
106 cells were plated and TLR8 was stimulated as above
for 24 hours. After incubation, supernatants were
collected and analyzed for IL12p40 protein secretion
by enzyme-linked immunosorbent assay (ELISA) (Cell
Sciences, Canton, MA, USA). In accordance with the
transcription data, we found a decrease in IL12p40
protein secreted from PBMCs from patients with MS
as compared to healthy controls after TLR8 stimulation
(mean ± SE = 717.7 ± 211.3 versus 2,401 ± 285.4 pg/ ml;
P <0.005) but not after PHA stimulation (mean ± SE =
843.5 ± 287.6 versus 709.4 ± 169.8 pg/ ml; P >0.05)
(Figure 2) indicating the cells from patients with MS
were capable of responding to the same level as cells
from healthy donors. No appreciable production of
IL12p40 was observed after stimulation with TLR3, 7
or 9 (Figure 2).
We next analyzed the baseline expression of TLR8 and
TLR3 in patients with MS as well as healthy donors. Using
RNA harvested from unstimulated cells as described above,
quantitative PCR was performed using primers specific for
TLR8 or TLR3 and GAPDH. TLR transcript expression
levels were determined by relative quantification as de-
scribed above. Cells from patients with MS showed a 2.7-
fold decrease in transcript levels of TLR8 (median ± 25%
to 75% interquartile range = 0.3 ± 0.1 to 0.6 versus 0.8 ±
0.6 to 1.2 relative expression; P <0.005) (Figure 3A); no dif-
ference in TLR3 expression was detected (median ± 25%
to 75% interquartile range = 2.8 ± 1.5 to 3.7 versus 2.7 ±
1.7 to 4.0 relative expression; P >0.05) as compared to
healthy donors (Figure 3B).
Conclusions
This study shows that patients with MS exhibit a pro-
found dysregulation of TLR8 signaling as compared to
healthy donors manifested by IL-12β transcript and IL-
12p40 protein production. The mechanism of depressed
responsiveness of TLR8 appears to be a result of de-
creased TLR8 baseline expression in PBMC from pa-






















































Figure 2 IL-12p40 protein expression in PBMC. IL-12p40 protein
expression is decreased in patients with MS as compared to healthy
donors after TLR8 stimulation (ANOVA with Bonferroni’s correction for
multiple comparisons, ** = P <0.005, n = 10 per group), but IL-12p40
protein expression was not different between patients with MS and
healthy donors after stimulation with PHA (n = 10 per group). No
appreciable production of IL-12p40 occurred after stimulation with TLR3,
7 or 9. Data shown are the mean ± SEM IL-12p40 protein concentration
in pg/ml. MS, multiple sclerosis; PBMC, peripheral blood mononuclear
















































Figure 3 TLR 8 and 3 gene expression in PBMC. Patients with MS
and healthy donors differ in baseline (A) TLR8 transcript expression
(Student’s unpaired two-tailed t-test, ** = P <0.005, n = 10 per
group) but not in (B) TLR3 transcript expression (n = 7 per group).
Data shown are median ± 25% to 75% interquartile range relative
TLR mRNA quantification at baseline for each individual normalized
to GAPDH and a reference sample. MS, multiple sclerosis; PBMC,
peripheral blood mononuclear cells; TLR, Toll-like receptor.
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patients with MS may be functionally hypoactive, resulting
in detectable under-production of IL-12β. IL12B encodes
the p40 subunit of IL-12 which forms both IL-12 and IL-
23, two cytokines that are considered a driving force in
EAE progression [13-16]. Although IL12p40 appears to
have a critical role in EAE, MS pathogenesis may not be
dependent on IL-12p40. A clinical trial using ustekinumab,
a monoclonal antibody against IL-12p40, in patients with
MS showed no beneficial clinical effect [16]. Therefore, the
lack of IL12p40 detected in our study does not conflict
with current data, although it seems counter-intuitive in an
auto-immune mediated disease. Our study also detected a
statistical difference in TNFα production after TLR3
stimulation; however, the expression values were low and
the difference was rather modest, hence its biological rele-
vance is unknown. We looked specifically at functionality
of a subset of TLRs with a limited cytokine output. Our
study is unique because we studied untreated patients in
the absence of a clinical relapse. We readily detected a ro-
bust difference in TLR8 function between patients with
MS and healthy donors. This finding may be clinically rele-
vant as TLR8 deficient mice have increased autoimmunity
[17]. Interplay between TLR8 loss and hyper-expression of
TLR7 has been documented in mice [17] and patients with
MS who are treated with INF-β1 therapy have an increase
in TLR7 expression [18]. TLR8 is the least well understood
of the human TLRs and our study provides additional evi-
dence that TLR8 needs further investigation and, similar to
the murine model, that human TLR8 deficiency may con-
tribute to autoimmune processes.
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